Immune Design Corp (IMDZ) Given Consensus Recommendation of “Buy” by Analysts

Shares of Immune Design Corp (NASDAQ:IMDZ) have been assigned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $10.75.

Several equities research analysts have recently commented on the company. ValuEngine raised Immune Design from a “strong sell” rating to a “sell” rating in a report on Thursday, May 17th. Jefferies Financial Group reaffirmed a “buy” rating and set a $8.00 target price on shares of Immune Design in a report on Thursday, March 15th. Finally, Zacks Investment Research raised Immune Design from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Tuesday, March 13th.

Shares of Immune Design traded down $0.30, hitting $4.45, during trading on Friday, MarketBeat reports. The stock had a trading volume of 280,400 shares, compared to its average volume of 390,367. The firm has a market cap of $223.78 million, a price-to-earnings ratio of -2.54 and a beta of 1.95. Immune Design has a fifty-two week low of $2.80 and a fifty-two week high of $13.05.

Immune Design (NASDAQ:IMDZ) last announced its earnings results on Wednesday, May 2nd. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.01. Immune Design had a negative return on equity of 52.00% and a negative net margin of 2,352.98%. The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $1.83 million. equities research analysts expect that Immune Design will post -1.27 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. DRW Securities LLC lifted its holdings in shares of Immune Design by 117.6% during the first quarter. DRW Securities LLC now owns 37,000 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 20,000 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Immune Design by 82.3% during the fourth quarter. California State Teachers Retirement System now owns 50,518 shares of the biotechnology company’s stock valued at $197,000 after purchasing an additional 22,799 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Immune Design by 59.7% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 54,543 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 20,400 shares during the period. Teachers Advisors LLC raised its position in Immune Design by 71.4% during the fourth quarter. Teachers Advisors LLC now owns 56,367 shares of the biotechnology company’s stock valued at $220,000 after buying an additional 23,475 shares during the period. Finally, TIAA CREF Investment Management LLC raised its position in Immune Design by 49.0% during the fourth quarter. TIAA CREF Investment Management LLC now owns 63,192 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 20,777 shares during the period. 50.70% of the stock is owned by institutional investors and hedge funds.

About Immune Design

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply